You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tyrosine kinase inhibitor

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +2 more
  • (no location specified)
Mar 27, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Liposarcoma, Metastatic Liposarcoma Trial in Boston, Saint Louis, New York (MGCD516)

Active, not recruiting
  • Liposarcoma
  • Metastatic Liposarcoma
  • Boston, Massachusetts
  • +2 more
Nov 23, 2022

Cancer, Cancer, Treatment-Related, Medication Adherence Trial in Chicago (Oncotool Intervention (symptom reporting + TKI

Completed
  • Cancer
  • +4 more
  • Oncotool Intervention (symptom reporting + TKI education)
  • Oncotool Control (health information)
  • Chicago, Illinois
    Northwestern University
Jan 25, 2023

Condition Vasoregulation Function Endothelium in CML Getting TKI

Recruiting
  • Chronic Myeloid Leukaemia
  • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
  • Moscow, Russian Federation
  • +1 more
Jan 11, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Cervical Cancer, Cervical Carcinoma Trial in Guangzhou (Zimberelimab, Lenvatinib)

Not yet recruiting
  • Cervical Cancer
  • Cervical Carcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

Completed
Has Results
  • Hepatitis
  • Safety and Tolerability
  • HEPLISAV-B
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 13, 2022

CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

Not yet recruiting
  • CML (Chronic Myelogenous Leukemia
  • (no location specified)
Jul 27, 2022

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

Not yet recruiting
  • Hepatocellular Carcinoma
  • +6 more
  • San Antonio, Texas
    Next Oncology
Aug 9, 2022

Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib Trial in Shanghai (drug, radiation, procedure)

Recruiting
  • Soft Tissue Sarcoma
  • +3 more
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Nov 1, 2022

TKI Discontinuation in CML Patients of China

Recruiting
  • Leukemia
  • +4 more
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Mar 15, 2022

    Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • +5 more
    • Orange, California
    • +13 more
    Nov 7, 2022

    Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI

    Active, not recruiting
    Has Results
    • Safety and Tolerability
    • +3 more
    • Zoster Vaccine Recombinant, Adjuvanted
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 10, 2022

    Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

    Withdrawn
    • Stage II Renal Cell Cancer
    • Stage III Renal Cell Cancer
    • (no location specified)
    Aug 11, 2022

    Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

    Recruiting
    • Mantle Cell Lymphoma
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

    Not yet recruiting
    • Ovarian Cancer
    • +4 more
    • (no location specified)
    Aug 8, 2022

    NSCLC Trial (AK119, AK112, Pemetrexed)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Nov 23, 2022

    Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer Trial (Q702, Pembrolizumab)

    Not yet recruiting
    • Esophageal Cancer
    • +3 more
    • (no location specified)
    Jun 27, 2022

    Nonproliferative Diabetic Retinopathy Trial (EYP-1901, Sham IVT)

    Not yet recruiting
    • Nonproliferative Diabetic Retinopathy
    • (no location specified)
    Aug 3, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +2 more
    • Duarte, California
    • +14 more
    Jan 27, 2023

    GIST, Malignant, CBT Trial in Pittsburgh (MAAT)

    Recruiting
    • GIST, Malignant
    • CBT
    • MAAT
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Apr 15, 2022